Strong Financial Performance
BWXT had a solid start in Q1 2025 with double-digit year-over-year revenue, adjusted EBITDA, and adjusted EPS growth. Revenue was $682 million, up 13%, and adjusted EPS was $0.91, up 20%.
Robust Bookings and Backlog
Commercial operations backlog reached $1.3 billion, up 78% year-over-year, driven by strong bookings in commercial power and nuclear medicine.
Strategic Contract Wins
BWXT won the management and operations contract for the Department of Energy's Strategic Petroleum Reserve and the NNSA's intent to award the Domestic Uranium Enrichment Centrifuge Experiment on a sole-source basis.
Expansion in Nuclear Capabilities
BWXT is expanding the Cambridge manufacturing plant by nearly 50% and progressing with the acquisition of Kinectrics, enhancing its nuclear services portfolio.
Government Operations Growth
Government operations had a strong quarter with 14% revenue growth and 17% adjusted EBITDA growth, driven by naval propulsion and special materials.
Advancements in Nuclear Medicine
BWXT Medical reported double-digit revenue and EBITDA growth, with expectations for full-year revenue growth of over 20%.